Public Companies
Filament Health Announces First Ever Nagoya Protocol-Compliant Shipment of Iboga from Gabon
Filament Health Corp. (OTCQB: FLHLF / NEO: FH / FSE: 7QS), a clinical-stage natural psychedelic drug development company, today announced the completion…
Filament Health Corp. (OTCQB: FLHLF / NEO: FH / FSE: 7QS), a clinical-stage natural psychedelic drug development company, today announced the completion of the first-ever Nagoya Protocol-compliant import of Tabernanthe iboga root from Gabon to Filament’s Metro Vancouver research and development facility.
The import was authorized by the Gabonese government under the Nagoya Protocol, an international agreement which ensures sharing of the benefits arising from the utilization of genetic resources in a fair and equitable way, and the Gabonese Convention on Biological Diversity. The iboga root will undergo analysis at Filament’s facility, and be transformed into total alkaloid iboga extract, in partnership with Terragnosis, a company dedicated to producing ethically sourced and high quality ibogaine and iboga extracts.
Jonathan Dickinson, Founder of Terragnosis“This is a significant accomplishment which will facilitate important healing work, while also supporting communities in Gabon. We have partnered closely with Filament Health, as well as with Blessings of the Forest Gabon and the A2E community that had such foresight to begin planting iboga almost 20 years ago. We are dedicated to this pathway of ensuring access and benefits for traditional knowledge holders in Gabon going forward.”
boga is a shrub which is native to Central Africa and contains ibogaine, a psychoactive compound. Traditionally used for ritual and ceremonial practices, iboga and ibogaine are believed to show promise for treating mental health conditions like substance use disorder. The first batch of extract will be delivered to Terragnosis’ partner, Ambio Life Sciences, which operates several retreat facilities in Mexico.
“Filament Health has the preeminent botanical extraction expertise and regulatory proficiency in the psychedelic industry,” said Benjamin Lightburn, CEO and Co-Founder of Filament Health. “We’re proud to combine these skills to accomplish the first ever Nagoya Protocol-compliant shipment of iboga from Gabon, and explore this promising yet under-researched drug.”
About Filament Health
Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament’s platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines. We are paving the way with the first-ever natural psychedelic drug candidates.
-
Psychedelics1 week ago
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
-
Law & Regulation1 week ago
Going concern warnings cloud Xtacy Therapeutics’ shrunk losses
-
Psilocybin1 week ago
Are Shrooms Legal in Oregon: Full Guide
-
Psychedelics1 week ago
Optimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)
-
Psychedelics1 week ago
Atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
-
Psychedelics1 week ago
Psyence Group’s NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
-
Law & Regulation1 week ago
Clearmind signs agreement with Hebrew University for psychedelic compound rights
-
Psilocybin7 days ago
California advances bill for psychedelics centers